691857-54-2

Usage

Uses

Used in Pharmaceutical Industry:
3-Benzofurancarboxylic acid, 5-cyclopropyl-2-(4-fluorophenyl)-6-[(methylsulfonyl)amino]is used as a precursor in the synthesis of new drugs for various medical conditions. Its unique chemical structure allows for the development of compounds with specific therapeutic properties, making it a valuable asset in medicinal chemistry research.
Used in Medicinal Chemistry Research:
3-Benzofurancarboxylic acid, 5-cyclopropyl-2-(4-fluorophenyl)-6-[(methylsulfonyl)amino]is utilized as a research tool in the field of medicinal chemistry to explore its potential as a lead compound for drug development. Its structural features and chemical properties are studied to understand its interactions with biological targets and to optimize its pharmacological profile for specific therapeutic applications.
Used in Drug Design and Optimization:
3-Benzofurancarboxylic acid, 5-cyclopropyl-2-(4-fluorophenyl)-6-[(methylsulfonyl)amino]serves as a starting point for drug design and optimization processes. Its chemical groups can be modified to enhance its pharmacokinetic and pharmacodynamic properties, improving its efficacy, safety, and selectivity in treating specific medical conditions.

Upstream product

• 1383851-17-9 ethyl 5-cyclopropyl-2-(4-fluorophenyl)-6-[(methylsulfonyl)amino]-1-benzofuran-3-carboxylate 
• 691856-86-7 ethyl 2-(4-fluorophenyl)-5-hydroxybenzofuran-3-carboxylate 
• 1999-00-4 ethyl 3-(4'-fluorophenyl)-3-oxopropionate 
• 691857-53-1 ethyl 6-amino-5-cyclopropyl-2-(4-fluorophenyl)benzofuran-3-carboxylate 
• 691857-52-0 ethyl 5-cyclopropyl-2-(4-fluorophenyl)-6-nitrobenzofuran-3-carboxylate 
• 691857-51-9 ethyl 2-(4-fluorophenyl)-6-nitro-5-(trifluoromethylsulfonyloxy)benzofuran-3-carboxylate 
• 691857-46-2 ethyl 2-(4-fluorophenyl)-5-hydroxy-6-nitrobenzofuran-3-carboxylate 
• 691857-07-5 ethyl 2-(4-fluorophenyl)-5-isopropoxy-6-nitrobenzofuran-3-carboxylate 
• 691856-87-8 ethyl 2-(4-fluorophenyl)-5-isopropoxybenzofuran-3-carboxylate 
• 1331942-88-1 methyl 2-(4-fluorophenyl)-5-[(1-methylethyl)oxy]-6-nitro-1-benzofuran-3-carboxylate 
• 1331942-87-0 methyl 2-(4-fluorophenyl)-5-[(1-methylethyl)oxy]-1-benzofuran-3-carboxylate 
• 1331942-99-4 methyl 6-[bis(methylsulfonyl)amino]-5-cyclopropyl-2-(4-fluorophenyl)-1-benzofuran-3-carboxylate 
• 1331942-98-3 methyl 6-amino-5-cyclopropyl-2-(4-fluorophenyl)-1-benzofuran-3-carboxylate 
• 1331942-97-2 methyl 5-cyclopropyl-2-(4-fluorophenyl)-6-nitro-1-benzofuran-3-carboxylate 

Downstream Products

• 691856-35-6 5-cyclopropyl-2-(4-fluorophenyl)-N-methyl-6-(methylsulfonamido)benzofuran-3-carboxamide 
• 1378429-90-3 N,5-dicyclopropyl-2-(4-fluorophenyl)-6-(methylsulfonamido)benzofuran-3-carboxamide 
• 1423007-46-8 (4-{N-[5-cyclopropyl-2-(4-fluorophenyl)-3-(methylcarbamoyl)-1-benzofuran-6-yl]methanesulfonamido}-3-fluorophenyl)boronic acid 
• 1423007-50-4 5-cyclopropyl-6-(N-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methylsulfonamido)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide 
• 1423007-49-1 6-[N-(4-bromo-2-fluorophenyl)methanesulfonamido]-5-cyclopropyl-2-(4-fluorophenyl)-N-methyl-1-benzofuran-3-carboxamide 
• 1423007-48-0 6-[N-(4-amino-2-fluorophenyl)methanesulfonamido]-5-cyclopropyl-2-(4-fluorophenyl)-N-methyl-1-benzofuran-3-carboxamide 
• 1423007-47-9 5-cyclopropyl-6-[N-(3-fluoro-4-nitrophenyl)methanesulfonamido]-2-(4-fluorophenyl)-N-methyl-1-benzofuran-3-carboxamide 

Relevant academic research and scientific papers

Convergent Synthesis of the NS5B Inhibitor GSK8175 Enabled by Transition Metal Catalysis

A convergent eight-stage synthesis of the boron-containing NS5B inhibitor GSK8175 is described. The previous route involves 13 steps in a completely linear sequence, with an overall 10% yield. Key issues include a multiday SNAr arylation of a s

INHIBITORS OF HEPATITIS C VIRUS POLYMERASE

The present invention provides, among other things, compounds represented by the general Formula I: (I) and pharmaceutically acceptable salts thereof, wherein L and A (and further substituents) are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.

THERAPEUTIC METHODS

The present invention features a method for the treatment of Hepatitis C in a human in need thereof comprising administering a compound of Formulas (II) or (IIB) described herein or a pharmaceutically acceptable salt thereof in combination with one or more alternative Hepatitis C therapeutic agents

BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS

The present invention features compounds of formula (I) and salts thereof, pharmaceutical compositions comprising said compounds, and uses of such compounds in treating or preventing viral infections, such as HCV infections, and diseases associated with such infections.

COMBINATION THERAPY METHOD FOR TREATING HEPATITIS C VIRUS INFECTION AND PHARMACEUTICAL COMPOSITIONS FOR USE THEREIN

Combination therapy methods for the treatment of hepatitis C virus infection and associated diseases, by the co-administration of 5-cyclopropyl-2- (4-fluoro-phenyl-6-[(2-hydroxy-ethyl)-methanesulfonyl-amino]-benzofuran- 3-carboxylic acid methylamide or a pharmaceutically acceptable salt thereof with natural, recombinant or modified interferon, that effectively inhibit viral replication.